叶酸靶向免疫疗法：癌症的被动和主动策略。
Folate-targeted immunotherapies: Passive and active strategies for cancer.
机构信息
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
Department of Biological Engineering, Biohybrid Systems Research Center (BSRC), Inha University, 100, Inha-ro, Incheon, 22212, Republic of Korea.
出版信息
Cytokine Growth Factor Rev. 2019 Feb;45:45-52. doi: 10.1016/j.cytogfr.2019.02.001. Epub 2019 Feb 7.
The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.
糖蛋白 FRα 是一种膜结合的转运蛋白，在健康细胞中受到免疫系统的保护。然而，它在各种恶性肿瘤中上调，参与癌症的发展，并且具有免疫原性。此外，FRα 是一种具有独特特性的肿瘤相关抗原，因此成为癌症免疫治疗开发的合适靶点。目前正在开发各种针对 FRα 的免疫治疗策略，并在临床上评估其治疗各种实体瘤的效果。这些方法包括被动抗 FRα 免疫疗法，如单克隆抗体，或主动免疫疗法，如嵌合抗原受体 T 细胞（CAR-T）、叶酸半抗原和疫苗。在这篇综述中，我们将探讨基于 FRα 的免疫治疗领域的进展，并讨论其在临床中的成功和不足之处。
Zotero 插件